BioNeutra Global Corporation
BGA.V
TSX
| Weiss Ratings | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.63 | |||
| Price History | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -70.00% | |||
| 2-Year Total Return | 20.00% | |||
| 3-Year Total Return | -77.78% | |||
| 5-Year Total Return | -86.36% | |||
| 52-Week High % Change | -81.25% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.16 | |||
| 52-Week Low Price | $0.03 | |||
| 52-Week Low Price (Date) | Oct 10, 2024 | |||
| 52-Week High Price (Date) | Mar 12, 2024 | |||
| Valuation | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 966.95K | |||
| Enterprise Value | 5.65M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | -72.68% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.17 | |||
| Price/Book (Q) | -0.23 | |||
| Enterprise Value/Revenue (TTM) | 0.71 | |||
| Price | $0.03 | |||
| Enterprise Value/EBITDA (TTM) | -371.88 | |||
| Enterprise Value/EBIT | -9.59 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 46.45M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604 210 5669 | |||
| Address | 1030 West Georgia Street Vancouver, BC V6E 2Y3 | |||
| Website | www.bioneutra.ca | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -7.43% | |||
| Profit Margin | -5.63% | |||
| Management Effectiveness | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -3.41% | |||
| Return on Equity | -- | |||
| Income Statement | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 7.98M | |||
| Total Revenue (TTM) | 7.98M | |||
| Revenue Per Share | $0.17 | |||
| Gross Profit (TTM) | 3.42M | |||
| EBITDA (TTM) | -15.30K | |||
| EBIT (TTM) | -593.00K | |||
| Net Income (TTM) | -450.10K | |||
| Net Income Avl. to Common (TTM) | -450.10K | |||
| Total Revenue Growth (Q YOY) | 18.35% | |||
| Earnings Growth (Q YOY) | 69.65% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | 67.41% | |||
| Balance Sheet | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 589.60K | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 3.90M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -6.09M | |||
| Current Ratio (Q) | 0.346 | |||
| Book Value Per Share (Q) | -$0.13 | |||
| Total Assets (Q) | 10.05M | |||
| Total Current Liabilities (Q) | 11.25M | |||
| Total Debt (Q) | 5.58M | |||
| Total Liabilities (Q) | 16.14M | |||
| Total Common Equity (Q) | -6.09M | |||
| Cash Flow | BGA.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -53.00K | |||
| Cash from Financing (TTM) | -109.50K | |||
| Net Change in Cash (TTM) | -6.30K | |||
| Levered Free Cash Flow (TTM) | -932.80K | |||
| Cash from Operations (TTM) | -375.90K | |||
